Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis

Clinical and Experimental Rheumatology

Volumn 31, Issue 1, 2013, Pages 31-39

  Moon, Su Jin ^a   Park, Hoon Suk ^a   Kwok, Seung Ki ^a   Ju, Ji Hyeon ^a   Kim, Ho Youn ^a   Park, Sung Hwan ^a  

^a Department of Anatomy   (South Korea)

Author keywords

End stage renal disease; Kidney transplantation; Lupus nephritis; Predictors; Prognosis

Indexed keywords

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; KOREA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL RATE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BIOPSY; CHI-SQUARE DISTRIBUTION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LUPUS NEPHRITIS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RENAL DIALYSIS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874842512     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. GOULET JR, MACKENZIE T, LEVINTON C, HAYSLETT JP, CIAMPI A, ESDAILE JM: The longterm prognosis of lupus nephritis: the impact of disease activity. J Rheumatol 1993; 20: 59-65.
2. MOJCIK CF, KLIPPEL JH: End-stage renal disease and systemic lupus erythematosus. Am J Med 1996; 101: 100-7.
3. CHEIGH JS, STENZEL KH: End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 1993; 21: 2-8.
4. MOK CC: Prognostic factors in lupus nephritis. Lupus 2005; 14: 39-44.
5. ORTEGA LM, SCHULTZ DR, LENZ O, PARDO V, CONTRERAS GN: Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010; 19: 557-74.
6. MORONI G, VENTURA D, RIVA P et al.: Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43: 28-36.
7. BERDEN JH: Lupus nephritis. Kidney Int 1997; 52: 538-58.
8. MOHAN S, RADHAKRISHNAN J: Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 2011; 75: 233-41.
9. ISENBERG D, APPEL GB, CONTRERAS G et al.: Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010; 49: 128-40.
10. NOSSENT HC, SWAAK TJ, BERDEN JH: Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE. Am J Med 1990; 89: 169-74.
11. NOSSENT HC, SWAAK TJ, BERDEN JH: Systemic lupus erythematosus after renal transplantation: patient and graft survival and disease activity. The Dutch Working Party on Systemic Lupus Erythematosus. Am Intern Med 1991; 114: 183-8.
12. GORAL S, YNARES C, SHAPPELL SB et al.: Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003; 75: 651-6.
13. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
14. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
15. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-32.
16. AUSTIN HA 3RD, MUENZ LR, JOYCE KM et al.: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-91.
17. DAVIES DF, SHOCK NW: Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496-507.
18. CROCA SC, RODRIGUES T, ISENBERG DA: Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011; 50: 1424-30.
19. NEUMANN K, WALLACE DJ, AZEN C et al.: Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995; 25: 47-55.
20. FAURSCHOU M, DREYER L, KAMPER AL, STARKLINT H, JACOBSEN S: Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010; 62: 873-80.
21. BONO L, CAMERON JS, HICKS JA: The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999; 92: 211-8.
22. MOK CC, YING KY, NG WL et al.: Longterm outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119: 355 e25-33.
23. WARD MM: Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med 2000; 160: 3136-40.
24. WARD MM: Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009; 36: 63-7.
25. CAMERON JS: Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-24.
26. COSTENBADER KH, DESAI A, ALARCON GS et al.: Trends in the incidence, demographics and outcomes of end-stage renal disease due to lupus nephritis in the U.S., 1995-2006. Arthritis Rheum 2011; 63: 1681-8.
27. RIETVELD A, BERDEN JH: Renal replacement therapy in lupus nephritis. Nephrol Dial Transplant 2008; 23: 3056-60.
28. BRUCE IN, HALLETT DC, GLADMAN DD, UROWITZ MB: Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. J Rheumatol 1999; 26: 1490-4.
29. OKANO K, YUMURA W, NITTA K et al.: Analysis of lupus activity in end-stage renal disease treated by hemodialysis. Intern Med 2001; 40: 598-602.
30. Renal transplantation in congenital and metabolic diseases. A report from the ASC/NIH renal transplant registry. JAMA 1975; 232: 148-53.
31. CHELAMCHARLA M, JAVAID B, BAIRD BC, GOLDFARB-RUMYANTZEV AS: The outcome of renal transplantation among systemic lupus erythematosus patients. Nephrol Dial Transplant 2007; 22: 3623-30.
32. MOSCA M, TANI C, CARLI L, BOMBARDIERI S: Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29: S126-9.
33. CHIEN JW, LIN CY, YANG LY: Correlation between anti-Ro/La titers and clinical findings of patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 2001; 64: 283-91.
34. TÁPANES FJ, VÁSQUEZ M, RAMÍREZ R, MATHEUS C, RODRÍGUEZ MA, BIANCO N: Cluster analysis of antinuclear autoantibodies in the prognosis of SLE nephropathy: are anti-extractable nuclear antibodies protective? Lupus 2000; 9: 437-44.
35. MIGLIORINI P, BALDINI C, ROCCHI V, BOMBARDIERI S: Anti-Sm and anti-RNP antibodies. Autoimmunity 2005; 38: 47-54.
36. ESDAILE JM, JOSEPH L, MACKENZIE T, KASHGARIAN M, HAYSLETT JP: The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994; 21: 2046-51.0.